Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01319422 · OUTCOME

To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.

Continuous Versus Intermittent Dosing Regimens for Pomalidomide in Relapsed/Refractory Multiple Myeloma · Source last updated 2016-08-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Research bone marrow aspirate is obtained at baseline and after completion of 2 cycles of therapy (approximately 56 days)

What was measured

Research bone marrow aspirate is obtained to assess response (optional, but recommended), and to document complete remission, if applicable. Correlation to be determined upon completion of study treatment

Analysis population: The actin polymerization assay that was to be used for this outcome was not reproducible and data were not analyzed.

Groups in this outcome

Pomalidomide 2 mg/d on 28 Days/28 Day Cycle

Pomalidomide: Comparison of different dosages and schedules of drug

Pomalidomide 4 mg/d on 21 Days/28 Day Cycle

Pomalidomide: Comparison of different dosages and schedules of drug

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Pomalidomide 2 mg/d on 28 Days/28 Day Cycle0
Pomalidomide 4 mg/d on 21 Days/28 Day Cycle0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Research bone marrow aspirate is obtained to assess response (optional, but recommended), and to document complete remission, if applicable. Correlation to be determined upon completion of study treatment
groups
  1. description
    Pomalidomide: Comparison of different dosages and schedules of drug
    id
    OG000
    title
    Pomalidomide 2 mg/d on 28 Days/28 Day Cycle
  2. description
    Pomalidomide: Comparison of different dosages and schedules of drug
    id
    OG001
    title
    Pomalidomide 4 mg/d on 21 Days/28 Day Cycle
population Description
The actin polymerization assay that was to be used for this outcome was not reproducible and data were not analyzed.
reporting Status
POSTED
time Frame
Research bone marrow aspirate is obtained at baseline and after completion of 2 cycles of therapy (approximately 56 days)
title
To Correlate Drug Induced Changes in F Actin Polymerization With Adverse Effects and Clinical Responses.
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice